skip to Main Content

Board of Directors

Chaim Hurvitz
Chairman of the Board

Chaim Hurvitz joined Galmed’s Board in 2011.

Mr. Hurvitz cur­rently serves as the CEO of CH Health, a private venture capital firm; a position he has held since 2011. Pre­vi­ously, he was a member of Teva’s senior man­agement team, serving as the Pres­ident of Teva Inter­na­tional Group from 2002 until 2010, as Pres­ident and CEO of Teva Phar­ma­ceu­ticals Europe from 1992 to 1999 and as Vice Pres­ident, Israeli Phar­ma­ceu­tical Sales from 1999 until 2002.

Addi­tionally, from 2010 until 2014, Mr. Hurvitz served as a member of the Board of Directors of Teva Phar­ma­ceu­ticals Indus­tries Ltd.

Mr. Hurvitz presently serves as the chairman of Polypid, Aero­dentis and the Jaffa Institute, and is a board member of Urogen and Cel­lixir. He is also a board member of the Man­u­fac­turers Asso­ci­ation of Israel, and chairs its phar­ma­ceu­tical branch.

He holds a Bachelor of Arts degree in political science and eco­nomics from Tel Aviv Uni­versity, which awarded in 1985.

Allen Baharaff

Mr. Baharaff is the co-founder of Galmed, and has served as CEO since 2012, and Pres­ident as of 2015. Pre­vi­ously, he held a number of senior exec­utive posi­tions, including SVP at Isramex Projects Ltd., and Man­aging Director of T+M Trusteeship & Man­agement. He also serves as a Director of the Tel-Aviv Museum of Arts and Exec­utive Director at The Rubin Museum.

Mr. Baharaff holds a Bachelor of Science degree from the Uni­versity of London (LSE) and LLB and MA degrees from Cam­bridge Uni­versity. Since 1993, Mr. Baharaff has been a member of the Israel Bar Asso­ci­ation.

Carol L. Brosgart, M.D.

Dr. Brosgart has served as a member of Galmed’s board of directors since 2017. Dr. Brosgart served as a member of Tobira Therapeutics’s Board of Directors from 2009 until it was acquired by Allergan in 2016. She is now a con­sultant to Allergan and a number of biotech­nology com­panies in the areas of liver disease and infec­tious disease. Dr. Brosgart cur­rently serves on the Steering Com­mittee of the National Viral Hepatitis Round­table, the Exec­utive Com­mittee of the Forum for Col­lab­o­rative Research, and the Steering Com­mittee of the HBV Cure Group at the Forum. She is active in the public policy arena for AASLD and IDSA/​HIVMA.

Dr. Brosgart served as Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and to the Viral Hepatitis Action Coalition at the CDC Foun­dation from 2011 to 2013. Dr. Brosgart has also served as a member on the faculty of the School of Med­icine at the Uni­versity of Cal­i­fornia, San Fran­cisco for the past three decades, where she is a Clinical Pro­fessor of Med­icine, Bio­sta­tistics and Epi­demi­ology in the Division of Global Health and Infec­tious Dis­eases. From 2011 until 2011, Dr. Brosgart served as Chief Medical Officer at biotech­nology company Alios Bio­Pharma, Inc. Prior to Alios, Dr. Brosgart served as Senior Vice Pres­ident and Chief Medical Officer of Children’s Hos­pital & Research Center in Oakland, Cal­i­fornia, from 2009 until Feb­ruary 2011.

Pre­vi­ously, she served for eleven years, from 1998 until 2009, at the bio­phar­ma­ceu­tical company Gilead Sci­ences, Inc., where she held a number of senior man­agement roles, most recently as Vice Pres­ident, Public Health and Policy and earlier as Vice Pres­ident, Clinical Research and Vice Pres­ident, Medical Affairs and Global Medical Director, Hepatitis. She led the clinical devel­opment of a number of agents at Gilead, including Viread and Hepsera. Prior to Gilead, Dr. Brosgart worked for more than 20 years in clinical care, research and teaching at several Bay Area medical centers. She was the founder and Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, Cal­i­fornia, from 1987 until 1998 and served as the Medical Director of Central Health Center, Oakland, Cal­i­fornia, of the Alameda County Health Care Ser­vices Agency.

Dr. Brosgart has also served on the boards of pri­vately held com­panies and public, not-for-profit domestic and global health orga­ni­za­tions. Dr. Brosgart received a B.S. in Com­munity Med­icine from the Uni­versity of Cal­i­fornia, Berkeley and received an M.D. from the Uni­versity of Cal­i­fornia, San Fran­cisco. Her res­i­dency training was in pedi­atrics, public health and pre­ventive med­icine at UCSF and UC Berkeley School of Public Health. She has pub­lished exten­sively in the areas of HIV, HBV, CMV, and liver disease.

William S. Marth

Mr. Marth has served as a member of Galmed’s board of directors since 2014. Mr. Marth cur­rently serves as Pres­ident and Chief Exec­utive Officer of Albany Mol­e­cular Research Inc. (AMRI) a position he has held since 2014. Mr. Marth is also former Director and Chairman of the Board of AMRI. From 2010 to 2012, Mr. Marth served as Pres­ident and Chief Exec­utive Officer of Teva Phar­ma­ceu­tical Indus­tries Ltd., in the Americas. From 2008 to 2010, he served as Chief Exec­utive Officer of Teva North America. From 2005 to 2008, Mr. Marth served as CEO of Teva USA.

In addition, Mr. Marth worked with several large equity firms pro­viding guidance on their healthcare invest­ments. He was a member of Teva’s global exec­utive man­agement team from 2007 to 2012. From 1999 to 2002, he was the Exec­utive Vice Pres­ident and Vice Pres­ident of Sales and Mar­keting for Teva USA. Prior to joining Teva USA, he held various posi­tions with the Apothecon division of Bristol-Myers Squibb Co. Mr. Marth is a phar­macist and is cur­rently the Chairman of the Board of Directors of Sor­rento Ther­a­peutics, and a director at the Uni­versity of Illinois at Chicago College of Pharmacy (UIC).

Pre­vi­ously, Mr. Marth served as the Chairman of the Board of the Generic Phar­ma­ceu­tical Asso­ci­ation (GPhA) in 2008 and 2009 and the American Society for Health-System Phar­ma­cists (ASHP) in 2010, and various boards and com­mittees, including the Uni­versity of the Sci­ences in Philadelphia and the Board of Ambas­sadors for John Hopkins’ Project Project RESTORE. Mr. Marth earned his B.Sc. in Pharmacy from the Uni­versity of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Man­agement, DeVry Uni­versity.

David Sidransky, M.D.
External Director

Dr. David Sidransky, has served as a member of Galmed’s board of directors since 2014. Dr. Sidransky is a renowned oncol­ogist and research sci­entist who was pro­filed by TIME mag­azine in 2001 as one of the top physi­cians and sci­en­tists in America. He is widely rec­og­nized for his work with early detection of cancer. Dr. Sidransky serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Com­pre­hensive Cancer Center at Johns Hopkins Uni­versity, and is a Pro­fessor of Oncology, Oto­laryn­gology, Cel­lular & Mol­e­cular Med­icine, Urology, Genetics, and Pathology at John Hopkins Uni­versity and Hos­pital.

He has authored more than 500 peer-reviewed pub­li­ca­tions, and has con­tributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotech­nology com­panies and holds numerous biotech­nology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt Inter­na­tional Prize from the German Society of Clinical Chem­istry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physi­cians, and the 2004 Hinda Rosenthal Award and 2017 Team Award pre­sented by the American Asso­ci­ation of Cancer Research. Dr. Sidransky pre­vi­ously served as Vice Chairman of the Board of Directors of ImClone.

He is Chairman of the Board of Advaxis Inc, Cham­pions Oncology, and Tamir Biotech­nology, and is on the Board of Directors of Rosetta Genomics Ltd and Orge­nesis. He is a current and pre­vious member of sci­en­tific advisory boards of cor­po­ra­tions and insti­tu­tions, including Amgen, Med­Immune, Roche and Veridex, LLC (a Johnson & Johnson diag­nostic company). In addition, Dr. Sidransky served as Director of The American Asso­ci­ation for Cancer Research from 2005 to 2008. He received his B.A. from Brandeis Uni­versity and his M.D. from the Baylor College of Med­icine.

Ran Oren, M.D.

Prof. Ran Oren, M.D. joined Galmed’s board of directors in, 2017 and serves as a member of our sci­en­tific advisory board since 2014. He has also served as the Company’s Chief Medical Officer from August 2016 to March 2017. Prof. Oren is a Pro­fessor of Gas­troen­terology & Hepa­tology at the Faculty of Med­icine, Hebrew Uni­versity of Jerusalem, Israel, and he is cur­rently the Head of the Institute of Gas­troen­terology and Liver Disease at Hadassah Ein Kerem Hopital, Jerusalem, Israel. In 2000, Prof. Oren estab­lished the Liver Unit at the Tel Aviv Sourasky Medical Center, where he also served as Chief of Med­icine from 2008 to 2010. Prof. Oren con­cur­rently served as the Pres­ident of the Israeli Asso­ci­ation for the Study of the Liver between 2007 and 2010.

Prof. Oren has pub­lished over the years in the fields of liver fibrosis, thyroid hormone effect on liver dis­eases and hepa­tocyte trans­plan­tation. In recent years his main research interests are in the field of non-alco­holic fatty liver disease (NAFLD) –epi­demi­ology, risk factors, diag­nosis and treatment. Prof. Oren cur­rently serves on the edi­torial board of Hepa­tology, the official journal of the American Asso­ci­ation for the Study of Liver Dis­eases (AASLD), and recently was the author of The Liver and Preg­nancy chapter in the Zakim & Boyer textbook of Hepa­tology. He received his M.D. from the Hebrew Uni­versity of Jerusalem, Israel.

Tali Yaron-Eldar
External Director

Tali Yaron-Eldar, an Israeli attorney spe­cial­izing in tax­ation, has served as a member of Galmed’s board of directors since 2014. Ms. Yaron-Eldar co-founded Yaron-Eldar, Paller, Schwartz & Co. Law Offices in 2013. She was a partner at the law firm of Tadmor & Co. from 2007 through 2012, and a partner at the law firm of Cohen, Yaron-Eldar & Co. between 2004 and 2007. From 2004 until 2008, Ms. Yaron-Eldar served as the Chief Exec­utive Officer of Arazim Investment Company. She has served in a variety of public posi­tions, including as Chief Legal Advisor to the Customs and V.A.T Department of the Finance Min­istry of the State of Israel from 1998 to 2001, and to the Com­mis­sioner of Income Tax and Real Property Tax Authority of the State of Israel from 2002 to 2004.

Ms. Yaron-Eldar also serves as a Director for a number of public com­panies, including Ros­setta Genomics Ltd., Medtechnica Ltd., Mag­icjack Vocaltec Ltd., Lodgia Rotex Invest­ments Ltd., Arko Holdings Ltd., Greenergy Renewable Energy Ltd., GO.D.M Invest­ments Ltd. and Tadea Tech­no­logical Devel­opment and Automation Ltd. She earned her M.B.A. spe­cial­izing in finance in 1995, and her LL.B. in 1987, both from Tel Aviv Uni­versity. Ms. Yaron-Eldar is a member of the Israeli Bar Asso­ci­ation.

Shmuel Nir

Shmuel Nir, has served as a member of Galmed’s board of directors since 2007. Mr. Nir serves as Pres­ident and Chief Exec­utive Officer of Tushia Con­sulting Engi­neers Ltd., and as Chairman of the Board of Directors of Matan Digital Printers Ltd. From 1998 to 2008, he served as Pres­ident and Chief Exec­utive Officer of Macpell Indus­tries Ltd.

Between 1991 and 1998, Mr. Nir was Exec­utive Vice Pres­ident of Oper­a­tions at Macpell Indus­tries Ltd. and Pres­ident and Chief Exec­utive Officer of two of its sub­sidiaries: New Net Indus­tries Ltd., and New Net Assets Ltd. Prior to 1991, Mr. Nir held man­agement posi­tions with Intel Cor­po­ration in Jerusalem, Israel and Tefen Man­agement Con­sulting. Between 1999 and 2006, Mr. Nir served as Man­aging Partner at Spring Venture Capital Fund. He earned a B.Sc. in Indus­trial Engi­neering and Man­agement from the Technion — Israel Institute of Tech­nology in Haifa in 1989.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, con­sectetur adip­iscing elit. Ut elit tellus, luctus nec ullam­corper mattis, pul­vinar dapibus leo.

Back To Top